Newer additions to this class include Zometa/Aclasta (zoledronic acid, Novartis; approved in 2007 in the US and EU), which has the advantage of convenient once-yearly dosing and high efficacy ...
“Obviously if you give it intravenously once a year, as with zoledronic acid [Aclasta/Reclast; Novartis], or subcutaneously twice a year, as with denosumab, you're going to have much higher ...